Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Irisbiosciences a New Player in 3D Cell Culture

Published: Friday, February 14, 2014
Last Updated: Friday, February 14, 2014
Bookmark and Share
Irisbiosciences is focused on the development, manufacturing and marketing of products for bio-/pharmaceutical research and development, namely 3D cell culture products, tissue models and human & stem cells for in-vitro experimentation.

Company premises include a GMP facility with clean rooms (Classes A, C and D) and the company operates 250 m2 of fully equipped BSL Level 2, R&D, Analytical and QC laboratories for development of medical devices and tissue engineering products. 

irisbiosciences provides 3D cell culture products , as well as contract research and manufacturing services in cell based essays and cell based products. 

Products

mimsys® for 3D Cell culture 
mimsys® G is a xeno-free and non-immunogenic hydrogel, easy to handle, for cell encapsulation in 3D experiments in vitro or in vivo. mimsys® G is nutrient permeable and allows long term 3D cell culture, at least 21 days of proliferation and survival. The transparency of mimsys® G hydrogel make it suitable for established laboratorial cell assays, such as cell differentiation, microscopy evaluations, viability protocols and histological procedures. Protocol handbook is available upon request. 

Human Mesenchymal Stem Cells 
High quality and high purity mesenchymal stem cells are obtained from human adipose tissue. These cells can be applied in a broad range of basic and applied research contexts. Tissue processing, cell isolation and cryopreservation are performed under Good Manufacturing Practices (cGMP), using xeno-free and GMP reagents. Cells have very low levels of manipulation which minimizes genomic instability. Frozen vials are provided with indication of donor age, gender, ethnicity, Body Mass Index (BMI) and anatomical harvesting location. Protocol handbook is available upon request. 

Services

Contract Research 
irisbiosciences provides contract research services on medical device and advanced therapy medicinal products, by encompassing experimental development, in vitro performance assessment and in vivo testing. Our skill set includes strong competence in biomaterials’ development and cell culturing technologies, and extensive knowledge and experience in tissue engineering and regenerative medicine. 

irisbiosciences provides: 

  • Biomaterials development and testing; 
  • Cell based assays development and validation; 
  • Cell isolation and cell manipulation protocol development; 
  • Development and testing of cell based products. 

Contract Manufacturing Services : 

irisbiosciences provides a wide range of cGMP services concerning human tissue, cells and related products, including tissue processing, manufacturing of cell-based products, as well as cell manufacturing and banking. 

The facility comprises 250 m2 of qualified controlled environment rooms (CERs), or clean rooms, and material pass-throughs. The CERs are designed to maximize environmental quality, allow the manufacturing of sterile products and are compliant with all the requirements of the European Union Tissue and Cells Directives (EUTCD) and the guidelines for cGMP.To insure the highest levels of quality and regulatory compliance, we have implemented and follow a complete Quality System in conformity with EU-GMP Guide/ICH Q7 and ISO 9001:2008. 

irisbiosciences performs a comprehensive range of analytical testing to ensure product quality and demonstrate the control of viable and non-viable particles, in all irisbiosciences CERs associated with the aseptic preparation process. Quality control tests include LAL test for bacterial endotoxin quantification; mycoplasma detection by conventional PCR, and microbial contaminants detection / Sterility tests. For detection of microbial contaminants, irisbiosciences is equipped with Bact/ALERT Microbial Detection System requirements. 

Our Facilities/Equipment description: 

  • 6 cGMP compliant cleanroom areas; 
  • 3 Grade C/ISO 7 manufacturing rooms fitted with aseptic Isolators with positive pressure; 
  • 1 Grade D/ISO 8 support room and cryostorage room; 
  • 2 HVAC systems for continuity of processing; 
  • Dedicated clean room and facility monitoring system; 
  • Dedicated manufacturing room for cell expansion; 
  • O2 and CO2 controlled incubation. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!